Selective targeting of high affinity ALPHA4 integrins as a safe treatment strategy for IBD
Ended Project Grant Awarded Last action
- Award ID
- R41DK127869
- Recipient
-
Aviara Pharmaceuticals Inc. UEI NL9PN5GW1VT7
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $296,724
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $296,724 |
Quick answers
Who received award R41DK127869?
R41DK127869 was awarded to Aviara Pharmaceuticals Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 16, 2020.
How much is award R41DK127869 worth?
$296,724 has been obligated on R41DK127869.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award